



Application of
Branellec et al.

Application No.: 09/787,995

Filed: July 9, 2001

Title: Use of Specific Hybrid Promoters For
Controlling Tissue Expression

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: To Be Assigned

Art Unit: To Be Assigned

I hereby certify that this correspondence is being deposited
with the United States Postal Service as First Class Mail in
an envelope addressed to Commissioner for Patents,
Washington, D.C. 20231, on

Date of Deposit

Signature

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

Sir:

Attached is a copy of the official Filing Receipt from the Patent and Trademark Office in the above-identified application, for which issuance of a corrected filing receipt is respectfully requested.

There is an error in that the domestic priority data as claimed by applicant should read:

**This application is a 371 of PCT/FR99/02265 09/23/1999
which claims benefit of 60/123,298 03/04/1999**

Under Foreign Applications, the following should be deleted:

UNITED STATES OF AMERICA 60123298 03/04/1999

The correction is not due to any error by Applicants and no fee is due.

Respectfully submitted,

William C. Coppola, Reg. No. 41,686
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626

Aventis Docket No. ST98032 US PCT

RECEIVED
JAN 16 2003
TECH CENTER 1600 2900



2002
DEC 13 2002
DEC 13 2002

Commissioner for Patents
Washington, DC 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/787,995	07/09/2001	1653	1656	ST98032		18	3

005487
ROSS J OEHLE
AVENTIS PHARMACEUTICALS INC.
ROUTE 202-206, MAIL CODE: D-303A
BRIDGEWATER, PA 08807



CONFIRMATION NO. 1245

FILING RECEIPT



OC000000009131685

Date Mailed: 11/21/2002

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Didier Branellec, Brie-Comte-Robert, FRANCE;
Raphael Dartell, Paris, FRANCE;
Abderrahim Mahfoudi, Marolles Enbrie, FRANCE;
Daniel Scherman, Paris, FRANCE;

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/FR99/02265 09/23/1999

which claims benefit of 40/123,298 03/04/1999

Foreign Applications

FRANCE 9812000 09/25/1998

UNITED STATES OF AMERICA 60123296 03/04/1999

RECEIVED
JAN 16 2003
TECH CENTER

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

Title

Use of specific hybrid promoters for controlling tissue expression

Preliminary Class
435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).